Coming off a few major acquisitions, the Summit, NJ-based biopharmaceutical company continued to gain in 2011. Celgene first made it onto this list in 2009, coming in at No. 22. Since then, it has continued to be among the Fortune's fastest growing companies every year as the company works to become an oncology leader.
Celgene continued winning with the successes of popular drugs Revlimid and Vidaza for blood and bone marrow conditions. For 2011, revenues rose by 34% to approximately $4.8 billion over the previous year.
The company has seen some setbacks, however. It has been trying to win approval in Europe to widen use of blood cancer drug Revlimid, but withdrew its application recently in a move that stunned investors. The drug is already approved in Europe and the U.S. to treat multiple myeloma, but Celgene has been seeking to offer the treatment sooner to myeloma patients and as a maintenance therapy.
Our annual list of high achievers is a guide to the most vibrant part of corporate America and beyond.
.
